Inventor
PETER ORDENTLICH
Inventor
US
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07KPeptides21%
G01NInvestigating or analysing materials by determining their chemical or physical properties11%
C07DHeterocyclic compounds5%
PatentTitleYear
12,564,590Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof202612,552,869CSF-1R antibodies for the treatment of chronic graft versus host disease202612,168,054Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody202412,000,829Selection of patients for combination therapy202411,397,184Selection of patients for combination therapy202211,324,822Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to SYNDAX PHARMACEUTICALS INC (6)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 6 | 2022–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 6 | 2022–2026 |